Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2009

01.03.2009 | Preclinical Study

The effect of thrombospondin-1 on breast cancer metastasis

verfasst von: Karen O. Yee, Caitlin M. Connolly, Mark Duquette, Shideh Kazerounian, Raymond Washington, Jack Lawler

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Thrombospondin-1 (TSP-1) has been proposed to have both pro-metastatic and anti-metastatic properties. To elucidate its role in breast cancer metastasis, we compared tumor progression in the polyomavirus middle T antigen (Pyt) transgenic mouse and the TSP-1-null Pyt transgenic mouse. We characterized the tumors in these mice at 45, 60 and 90 days of age. Tumor size, areas of necrosis, macrophage infiltration, levels of active and total TGF-β, vessel morphology, and lung and blood metastasis were measured in these mice. Mammary tumors were larger in the TSP-1-null mouse, and vessels were larger, but fewer in number in these tumors. The level of total TGF-β was significantly higher in the Pyt tumors at 90 days of age. Importantly, significantly fewer metastases were observed in the lungs of the TSP-1-null/Pyt mouse. Primary Pyt tumor cells were more migratory than TSP-1-null Pyt tumor cells on collagen. Treatment of Pyt mice with recombinant proteins that contain the type-1 repeats of TSP-1 resulted in decreased primary tumor growth and metastasis. Sequences that are involved in CD36 binding and those required for TGF-β activation mediated the inhibition of primary tumor growth. Thus, TSP-1 in the mammary tumor microenvironment inhibits angiogenesis and tumor growth, but promotes metastasis to the lung in the Pyt transgenic mouse. The ability of TSP-1 to support metastasis correlates with its ability to promote tumor cell migration.
Literatur
1.
Zurück zum Zitat Chen H, Herndon ME, Lawler J (2000) The cell biology of thrombospondin-1. Matrix Biol 19:597–614PubMedCrossRef Chen H, Herndon ME, Lawler J (2000) The cell biology of thrombospondin-1. Matrix Biol 19:597–614PubMedCrossRef
2.
Zurück zum Zitat Lawler J (2002) Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 6:1–12PubMedCrossRef Lawler J (2002) Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 6:1–12PubMedCrossRef
3.
Zurück zum Zitat Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E, Watnick RS, Straume O, Akslen LA, Folkman J, Almog N (2006) A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 98:316–325PubMed Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E, Watnick RS, Straume O, Akslen LA, Folkman J, Almog N (2006) A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 98:316–325PubMed
4.
Zurück zum Zitat Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA (2003) Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 3:219–231PubMedCrossRef Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA (2003) Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 3:219–231PubMedCrossRef
5.
Zurück zum Zitat Lawler J, Miao WM, Duquette M, Bouck N, Bronson RT, Hynes RO (2001) Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am J Pathol 159:1949–1956PubMed Lawler J, Miao WM, Duquette M, Bouck N, Bronson RT, Hynes RO (2001) Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am J Pathol 159:1949–1956PubMed
6.
Zurück zum Zitat Volpert OV, Pili R, Sikder HA, Nelius T, Zaichuk T, Morris C, Shiflett CB, Devlin MK, Conant K, Alani RM (2002) Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell 2:473–483PubMedCrossRef Volpert OV, Pili R, Sikder HA, Nelius T, Zaichuk T, Morris C, Shiflett CB, Devlin MK, Conant K, Alani RM (2002) Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell 2:473–483PubMedCrossRef
7.
Zurück zum Zitat Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK, Tognazzi K, Dvorak HF (1999) Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 5:1041–1056PubMed Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK, Tognazzi K, Dvorak HF (1999) Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 5:1041–1056PubMed
8.
Zurück zum Zitat Schultz-Cherry S, Lawler J, Murphy-Ullrich JE (1994) The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta. J Biol Chem 269:26783–26788PubMed Schultz-Cherry S, Lawler J, Murphy-Ullrich JE (1994) The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta. J Biol Chem 269:26783–26788PubMed
9.
Zurück zum Zitat Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N (1998) Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 93:1159–1170PubMedCrossRef Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N (1998) Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 93:1159–1170PubMedCrossRef
10.
Zurück zum Zitat Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML (2001) Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 98:12485–12490PubMedCrossRef Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML (2001) Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 98:12485–12490PubMedCrossRef
11.
Zurück zum Zitat Gupta K, Gupta P, Wild R, Ramakrishnan S, Hebbel RP (1999) Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 3:147–158PubMedCrossRef Gupta K, Gupta P, Wild R, Ramakrishnan S, Hebbel RP (1999) Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 3:147–158PubMedCrossRef
12.
Zurück zum Zitat Bein K, Simons M (2000) Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem 275:32167–32173PubMedCrossRef Bein K, Simons M (2000) Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem 275:32167–32173PubMedCrossRef
13.
Zurück zum Zitat Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, Amin M, Bouck NP (2002) Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 8:349–357PubMedCrossRef Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, Amin M, Bouck NP (2002) Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 8:349–357PubMedCrossRef
14.
Zurück zum Zitat Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N (2000) Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6:41–48PubMedCrossRef Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N (2000) Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6:41–48PubMedCrossRef
15.
Zurück zum Zitat Nor JE, Mitra RS, Sutorik MM, Mooney DJ, Castle VP, Polverini PJ (2000) Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J Vasc Res 37:209–218PubMedCrossRef Nor JE, Mitra RS, Sutorik MM, Mooney DJ, Castle VP, Polverini PJ (2000) Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J Vasc Res 37:209–218PubMedCrossRef
16.
Zurück zum Zitat Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin DJ, D’Amato RJ, Kerbel RS (2005) Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7:101–111PubMed Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin DJ, D’Amato RJ, Kerbel RS (2005) Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7:101–111PubMed
17.
Zurück zum Zitat Rafii DC, Psaila B, Butler J, Jin DK, Lyden D (2008) Regulation of vasculogenesis by platelet-mediated recruitment of bone marrow derived cells. Arterioscler Thromb Vasc Biol 28:217–222PubMedCrossRef Rafii DC, Psaila B, Butler J, Jin DK, Lyden D (2008) Regulation of vasculogenesis by platelet-mediated recruitment of bone marrow derived cells. Arterioscler Thromb Vasc Biol 28:217–222PubMedCrossRef
18.
Zurück zum Zitat Magnetto S, Bruno-Bossio G, Voland C, Lecerf J, Lawler J, Delmas P, Silverstein R, Clezardin P (1998) CD36 mediates binding of soluble thrombospondin-1 but not cell adhesion and haptotaxis on immobilized thrombospondin-1. Cell Biochem Funct 16:211–221PubMedCrossRef Magnetto S, Bruno-Bossio G, Voland C, Lecerf J, Lawler J, Delmas P, Silverstein R, Clezardin P (1998) CD36 mediates binding of soluble thrombospondin-1 but not cell adhesion and haptotaxis on immobilized thrombospondin-1. Cell Biochem Funct 16:211–221PubMedCrossRef
19.
Zurück zum Zitat Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP (1997) CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138:707–717PubMedCrossRef Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP (1997) CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138:707–717PubMedCrossRef
20.
Zurück zum Zitat Urquidi V, Sloan D, Kawai K, Agarwal D, Woodman AC, Tarin D, Goodison S (2002) Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clin Cancer Res 8:61–74PubMed Urquidi V, Sloan D, Kawai K, Agarwal D, Woodman AC, Tarin D, Goodison S (2002) Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clin Cancer Res 8:61–74PubMed
21.
Zurück zum Zitat Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS (1994) Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 54:6504–6511PubMed Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS (1994) Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 54:6504–6511PubMed
22.
Zurück zum Zitat Yabkowitz R, Mansfield PJ, Dixit VM, Suchard SJ (1993) Motility of human carcinoma cells in response to thrombospondin: relationship to metastatic potential and thrombospondin structural domains. Cancer Res 53:378–387PubMed Yabkowitz R, Mansfield PJ, Dixit VM, Suchard SJ (1993) Motility of human carcinoma cells in response to thrombospondin: relationship to metastatic potential and thrombospondin structural domains. Cancer Res 53:378–387PubMed
23.
24.
Zurück zum Zitat Albo D, Rothman VL, Roberts DD, Tuszynski GP (2000) Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor. Br J Cancer 83:298–306PubMedCrossRef Albo D, Rothman VL, Roberts DD, Tuszynski GP (2000) Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor. Br J Cancer 83:298–306PubMedCrossRef
25.
Zurück zum Zitat Albo D, Berger DH, Wang TN, Hu X, Rothman V, Tuszynski GP (1997) Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system. Surgery 122:493–499; discussion 499–500PubMedCrossRef Albo D, Berger DH, Wang TN, Hu X, Rothman V, Tuszynski GP (1997) Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system. Surgery 122:493–499; discussion 499–500PubMedCrossRef
26.
Zurück zum Zitat Wang TN, Qian X, Granick MS, Solomon MP, Rothman VL, Berger DH, Tuszynski GP (1996) Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer. J Surg Res 63:39–43PubMedCrossRef Wang TN, Qian X, Granick MS, Solomon MP, Rothman VL, Berger DH, Tuszynski GP (1996) Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer. J Surg Res 63:39–43PubMedCrossRef
27.
Zurück zum Zitat Albo D, Berger DH, Tuszynski GP (1998) The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion. J Surg Res 76:86–90PubMedCrossRef Albo D, Berger DH, Tuszynski GP (1998) The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion. J Surg Res 76:86–90PubMedCrossRef
28.
Zurück zum Zitat Albo D, Arnoletti JP, Castiglioni A, Granick MS, Solomon MP, Rothman VL, Tuszynski GP (1994) Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro. Biochem Biophys Res Commun 203:857–865PubMedCrossRef Albo D, Arnoletti JP, Castiglioni A, Granick MS, Solomon MP, Rothman VL, Tuszynski GP (1994) Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro. Biochem Biophys Res Commun 203:857–865PubMedCrossRef
29.
Zurück zum Zitat Wang TN, Qian XH, Granick MS, Solomon MP, Rothman VL, Tuszynski GP (1995) The effect of thrombospondin on oral squamous carcinoma cell invasion of collagen. Am J Surg 170:502–505PubMedCrossRef Wang TN, Qian XH, Granick MS, Solomon MP, Rothman VL, Tuszynski GP (1995) The effect of thrombospondin on oral squamous carcinoma cell invasion of collagen. Am J Surg 170:502–505PubMedCrossRef
30.
Zurück zum Zitat Arnoletti JP, Albo D, Granick MS, Solomon MP, Castiglioni A, Rothman VL, Tuszynski GP (1995) Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells. Cancer 76:998–1005PubMedCrossRef Arnoletti JP, Albo D, Granick MS, Solomon MP, Castiglioni A, Rothman VL, Tuszynski GP (1995) Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells. Cancer 76:998–1005PubMedCrossRef
31.
Zurück zum Zitat Guy CT, Cardiff RD, Muller WJ (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12:954–961PubMed Guy CT, Cardiff RD, Muller WJ (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12:954–961PubMed
32.
Zurück zum Zitat Maglione JE, Moghanaki D, Young LJ, Manner CK, Ellies LG, Joseph SO, Nicholson B, Cardiff RD, MacLeod CL (2001) Transgenic Polyoma middle-T mice model premalignant mammary disease. Cancer Res 61:8298–8305PubMed Maglione JE, Moghanaki D, Young LJ, Manner CK, Ellies LG, Joseph SO, Nicholson B, Cardiff RD, MacLeod CL (2001) Transgenic Polyoma middle-T mice model premalignant mammary disease. Cancer Res 61:8298–8305PubMed
33.
Zurück zum Zitat Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW (2003) Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163:2113–2126PubMed Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW (2003) Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163:2113–2126PubMed
34.
Zurück zum Zitat Lawler J, Sunday M, Thibert V, Duquette M, George EL, Rayburn H, Hynes RO (1998) Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 101:982–992PubMedCrossRef Lawler J, Sunday M, Thibert V, Duquette M, George EL, Rayburn H, Hynes RO (1998) Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 101:982–992PubMedCrossRef
35.
Zurück zum Zitat Miao WM, Seng WL, Duquette M, Lawler P, Laus C, Lawler J (2001) Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. Cancer Res 61:7830–7839PubMed Miao WM, Seng WL, Duquette M, Lawler P, Laus C, Lawler J (2001) Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. Cancer Res 61:7830–7839PubMed
36.
Zurück zum Zitat Yee KO, Streit M, Hawighorst T, Detmar M, Lawler J (2004) Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta. Am J Pathol 165:541–552PubMed Yee KO, Streit M, Hawighorst T, Detmar M, Lawler J (2004) Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta. Am J Pathol 165:541–552PubMed
37.
Zurück zum Zitat Inoue T, Plieth D, Venkov CD, Xu C, Neilson EG (2005) Antibodies against macrophages that overlap in specificity with fibroblasts. Kidney Int 67:2488–2493PubMedCrossRef Inoue T, Plieth D, Venkov CD, Xu C, Neilson EG (2005) Antibodies against macrophages that overlap in specificity with fibroblasts. Kidney Int 67:2488–2493PubMedCrossRef
38.
Zurück zum Zitat Lanari C, Luthy I, Lamb CA, Fabris V, Pagano E, Helguero LA, Sanjuan N, Merani S, Molinolo A (2001) Five novel hormone-responsive cell lines derived frommurine mamnary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins. Cancer Res 61:293–302PubMed Lanari C, Luthy I, Lamb CA, Fabris V, Pagano E, Helguero LA, Sanjuan N, Merani S, Molinolo A (2001) Five novel hormone-responsive cell lines derived frommurine mamnary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins. Cancer Res 61:293–302PubMed
39.
Zurück zum Zitat Lin EY, Pollard JW (2004) Macrophages: modulators of breast cancer progression. Novartis Found Symp 256:158–168; discussion 168–172, 259–169PubMedCrossRef Lin EY, Pollard JW (2004) Macrophages: modulators of breast cancer progression. Novartis Found Symp 256:158–168; discussion 168–172, 259–169PubMedCrossRef
40.
Zurück zum Zitat Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, Pollard JW (2006) Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66:11238–11246PubMedCrossRef Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, Pollard JW (2006) Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66:11238–11246PubMedCrossRef
41.
Zurück zum Zitat Lin EY, Pollard JW (2007) Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res 67:5064–5066PubMedCrossRef Lin EY, Pollard JW (2007) Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res 67:5064–5066PubMedCrossRef
42.
Zurück zum Zitat Yee KO, Connolly CM, Pines M, Lawler J (2006) Halofuginone inhibits tumor growth in the polyoma middle T antigen mouse via a thrombospondin-1 independent mechanism. Cancer Biol Ther 5:218–224PubMed Yee KO, Connolly CM, Pines M, Lawler J (2006) Halofuginone inhibits tumor growth in the polyoma middle T antigen mouse via a thrombospondin-1 independent mechanism. Cancer Biol Ther 5:218–224PubMed
43.
Zurück zum Zitat Zhang X, Lawler J (2007) Thrombospondin-based antiangiogenic therapy. Microvasc Res 74:90–99PubMedCrossRef Zhang X, Lawler J (2007) Thrombospondin-based antiangiogenic therapy. Microvasc Res 74:90–99PubMedCrossRef
44.
Zurück zum Zitat Anderson JC, Grammer JR, Wang W, Nabors LB, Henkin J, Stewart JE Jr, Gladson CL (2007) ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. Cancer Biol Ther 6:454–462PubMedCrossRef Anderson JC, Grammer JR, Wang W, Nabors LB, Henkin J, Stewart JE Jr, Gladson CL (2007) ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. Cancer Biol Ther 6:454–462PubMedCrossRef
45.
Zurück zum Zitat Isenberg JS, Yu C, Roberts DD (2008) Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells. Biochem Pharmacol 75:875–882PubMedCrossRef Isenberg JS, Yu C, Roberts DD (2008) Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells. Biochem Pharmacol 75:875–882PubMedCrossRef
46.
Zurück zum Zitat Harpel JG, Schultz-Cherry S, Murphy-Ullrich JE, Rifkin DB (2001) Tamoxifen and estrogen effects on TGF-beta formation: role of thrombospondin-1, alphavbeta3, and integrin-associated protein. Biochem Biophys Res Commun 284:11–14PubMedCrossRef Harpel JG, Schultz-Cherry S, Murphy-Ullrich JE, Rifkin DB (2001) Tamoxifen and estrogen effects on TGF-beta formation: role of thrombospondin-1, alphavbeta3, and integrin-associated protein. Biochem Biophys Res Commun 284:11–14PubMedCrossRef
47.
Zurück zum Zitat Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE (1999) The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta. J Biol Chem 274:13586–13593PubMedCrossRef Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE (1999) The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta. J Biol Chem 274:13586–13593PubMedCrossRef
48.
Zurück zum Zitat Ribeiro SM, Schultz-Cherry S, Murphy-Ullrich JE (1995) Heparin-binding vitronectin up-regulates latent TGF-beta production by bovine aortic endothelial cells. J Cell Sci 108(Pt 4):1553–1561PubMed Ribeiro SM, Schultz-Cherry S, Murphy-Ullrich JE (1995) Heparin-binding vitronectin up-regulates latent TGF-beta production by bovine aortic endothelial cells. J Cell Sci 108(Pt 4):1553–1561PubMed
49.
Zurück zum Zitat Schultz-Cherry S, Chen H, Mosher DF, Misenheimer TM, Krutzsch HC, Roberts DD, Murphy-Ullrich JE (1995) Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J Biol Chem 270:7304–7310PubMedCrossRef Schultz-Cherry S, Chen H, Mosher DF, Misenheimer TM, Krutzsch HC, Roberts DD, Murphy-Ullrich JE (1995) Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J Biol Chem 270:7304–7310PubMedCrossRef
50.
Zurück zum Zitat Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE (1994) Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J Biol Chem 269:26775–26782PubMed Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE (1994) Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J Biol Chem 269:26775–26782PubMed
51.
Zurück zum Zitat Schultz-Cherry S, Murphy-Ullrich JE (1993) Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J Cell Biol 122:923–932PubMedCrossRef Schultz-Cherry S, Murphy-Ullrich JE (1993) Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J Cell Biol 122:923–932PubMedCrossRef
52.
Zurück zum Zitat Murphy-Ullrich JE, Schultz-Cherry S, Hook M (1992) Transforming growth factor-beta complexes with thrombospondin. Mol Biol Cell 3:181–188PubMed Murphy-Ullrich JE, Schultz-Cherry S, Hook M (1992) Transforming growth factor-beta complexes with thrombospondin. Mol Biol Cell 3:181–188PubMed
53.
Zurück zum Zitat Tan K, Duquette M, Liu JH, Dong Y, Zhang R, Joachimiak A, Lawler J, Wang JH (2002) Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and its biological implication. J Cell Biol 159:373–382PubMedCrossRef Tan K, Duquette M, Liu JH, Dong Y, Zhang R, Joachimiak A, Lawler J, Wang JH (2002) Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and its biological implication. J Cell Biol 159:373–382PubMedCrossRef
54.
Zurück zum Zitat Dawson DW, Volpert OV, Pearce SF, Schneider AJ, Silverstein RL, Henkin J, Bouck NP (1999) Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol 55:332–338PubMed Dawson DW, Volpert OV, Pearce SF, Schneider AJ, Silverstein RL, Henkin J, Bouck NP (1999) Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol 55:332–338PubMed
55.
Zurück zum Zitat Simantov R, Silverstein RL (2003) CD36: a critical anti-angiogenic receptor. Front Biosci 8:s874–s882PubMedCrossRef Simantov R, Silverstein RL (2003) CD36: a critical anti-angiogenic receptor. Front Biosci 8:s874–s882PubMedCrossRef
56.
Zurück zum Zitat Nakagawa T, Martinez SR, Goto Y, Koyanagi K, Kitago M, Shingai T, Elashoff DA, Ye X, Singer FR, Giuliano AE, Hoon DS (2007) Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes. Clin Cancer Res 13:4105–4110PubMedCrossRef Nakagawa T, Martinez SR, Goto Y, Koyanagi K, Kitago M, Shingai T, Elashoff DA, Ye X, Singer FR, Giuliano AE, Hoon DS (2007) Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes. Clin Cancer Res 13:4105–4110PubMedCrossRef
57.
Zurück zum Zitat Alix-Panabieres C, Muller V, Pantel K (2007) Current status in human breast cancer micrometastasis. Curr Opin Oncol 19:558–563PubMed Alix-Panabieres C, Muller V, Pantel K (2007) Current status in human breast cancer micrometastasis. Curr Opin Oncol 19:558–563PubMed
58.
Zurück zum Zitat Lang JE, Hall CS, Singh B, Lucci A (2007) Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application? Expert Rev Anticancer Ther 7:1463–1472PubMedCrossRef Lang JE, Hall CS, Singh B, Lucci A (2007) Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application? Expert Rev Anticancer Ther 7:1463–1472PubMedCrossRef
59.
Zurück zum Zitat Bornstein P, Sage EH (2002) Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 14:608–616PubMedCrossRef Bornstein P, Sage EH (2002) Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 14:608–616PubMedCrossRef
60.
Zurück zum Zitat Orend G, Chiquet-Ehrismann R (2006) Tenascin-C induced signaling in cancer. Cancer Lett 244:143–163PubMedCrossRef Orend G, Chiquet-Ehrismann R (2006) Tenascin-C induced signaling in cancer. Cancer Lett 244:143–163PubMedCrossRef
61.
Zurück zum Zitat Tuck AB, Chambers AF, Allan AL (2007) Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem 102:859–868PubMedCrossRef Tuck AB, Chambers AF, Allan AL (2007) Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem 102:859–868PubMedCrossRef
62.
Zurück zum Zitat Moura R, Tjwa M, Vandervoort P, Cludts K, Hoylaerts MF (2007) Thrombospondin-1 activates medial smooth muscle cells and triggers neointima formation upon mouse carotid artery ligation. Arterioscler Thromb Vasc Biol 27:2163–2169PubMedCrossRef Moura R, Tjwa M, Vandervoort P, Cludts K, Hoylaerts MF (2007) Thrombospondin-1 activates medial smooth muscle cells and triggers neointima formation upon mouse carotid artery ligation. Arterioscler Thromb Vasc Biol 27:2163–2169PubMedCrossRef
63.
Zurück zum Zitat Tuszynski GP, Gasic TB, Rothman VL, Knudsen KA, Gasic GJ (1987) Thrombospondin, a potentiator of tumor cell metastasis. Cancer Res 47:4130–4133PubMed Tuszynski GP, Gasic TB, Rothman VL, Knudsen KA, Gasic GJ (1987) Thrombospondin, a potentiator of tumor cell metastasis. Cancer Res 47:4130–4133PubMed
64.
Zurück zum Zitat Wang TN, Qian XH, Granick MS, Solomon MP, Rothman VL, Berger DH, Tuszynski GP (1996) Inhibition of breast cancer progression by an antibody to a thrombospondin-1 receptor. Surgery 120:449–454PubMedCrossRef Wang TN, Qian XH, Granick MS, Solomon MP, Rothman VL, Berger DH, Tuszynski GP (1996) Inhibition of breast cancer progression by an antibody to a thrombospondin-1 receptor. Surgery 120:449–454PubMedCrossRef
65.
Zurück zum Zitat Zhang X, Galardi E, Duquette M, Delic M, Lawler J, Parangi S (2005) Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model. Clin Cancer Res 11:2337–2344PubMedCrossRef Zhang X, Galardi E, Duquette M, Delic M, Lawler J, Parangi S (2005) Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model. Clin Cancer Res 11:2337–2344PubMedCrossRef
66.
Zurück zum Zitat Byrne GJ, Hayden KE, McDowell G, Lang H, Kirwan CC, Tetlow L, Kumar S, Bundred NJ (2007) Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer. Int J Oncol 31:1127–1132PubMed Byrne GJ, Hayden KE, McDowell G, Lang H, Kirwan CC, Tetlow L, Kumar S, Bundred NJ (2007) Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer. Int J Oncol 31:1127–1132PubMed
Metadaten
Titel
The effect of thrombospondin-1 on breast cancer metastasis
verfasst von
Karen O. Yee
Caitlin M. Connolly
Mark Duquette
Shideh Kazerounian
Raymond Washington
Jack Lawler
Publikationsdatum
01.03.2009
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2009
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-9992-6

Weitere Artikel der Ausgabe 1/2009

Breast Cancer Research and Treatment 1/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.